AR040083A1 - Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac - Google Patents

Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac

Info

Publication number
AR040083A1
AR040083A1 ARP030101754A ARP030101754A AR040083A1 AR 040083 A1 AR040083 A1 AR 040083A1 AR P030101754 A ARP030101754 A AR P030101754A AR P030101754 A ARP030101754 A AR P030101754A AR 040083 A1 AR040083 A1 AR 040083A1
Authority
AR
Argentina
Prior art keywords
prepare
composition
compound
procedure
oxo
Prior art date
Application number
ARP030101754A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR040083A1 publication Critical patent/AR040083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto mimético de la trombopoyetina, que es la sal de bis-(monoetanolamina) del ácido 3'-[(2Z)-[1-(3,4-dimetil-fenil)-1,5-dihidro-3-metil-5-oxo-4H-pirazol-4-iliden]hidrazino]-2'-hidroxi-[1,1'-bifenil]-3-carboxílico. Procedimiento para prepararlo que comprende: i) disolver el ácido 3-'-[(2Z)-[1-(3,4-dimetilfenil)-1,5-dihidro-3-metil-5-oxo-4H-pirazol-4-iliden]-hidrazino]-2'-hidroxi-[1,1'-bifenil]-3-carboxilico en un disolvente orgánico apropiado, para formar una solución; ii) agregar dos o más equivalentes de etanolamina a la solución; y iii) aislar el compuesto preparado. Composición farmacéutica que lo comprende junto con un vehículo o diluyente farmacéuticamente aceptable, y procedimiento para preparar dicha composición. Uso del compuesto para preparar la composición para tratar la trombocitopenia en un mamífero, incluido el hombre, que lo requiere, y que comprende administrar a dicho mamífero una cantidad terapéuticamente eficaz del compuesto. Métodos in vitro o ex vivo para potenciar: la estimulación de la maduración de megacariocitos y/o la producción de plaquetas; la supervivencia y/o proliferación de células madre, células de médula ósea, células del cordón umbilical, células de sangre periférica u otros tipos de células que expresan el receptor de TPO en cultivo; y la estimulación de producción de neutrófilos, donde se emplea dicho compuesto.
ARP030101754A 2002-05-22 2003-05-20 Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac AR040083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38287102P 2002-05-22 2002-05-22

Publications (1)

Publication Number Publication Date
AR040083A1 true AR040083A1 (es) 2005-03-16

Family

ID=29584468

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101754A AR040083A1 (es) 2002-05-22 2003-05-20 Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac

Country Status (29)

Country Link
US (6) US7547719B2 (es)
EP (2) EP1534390B1 (es)
JP (2) JP4612414B2 (es)
KR (2) KR101090643B1 (es)
CN (1) CN100542530C (es)
AR (1) AR040083A1 (es)
AT (1) ATE452683T1 (es)
AU (1) AU2003241587B2 (es)
BR (1) BRPI0310094B8 (es)
CA (1) CA2486697C (es)
CY (1) CY1109912T1 (es)
DE (1) DE60330674D1 (es)
DK (1) DK1534390T3 (es)
ES (1) ES2338108T3 (es)
HK (1) HK1078039A1 (es)
IL (2) IL164966A0 (es)
IS (1) IS2770B (es)
LT (1) LTC1534390I2 (es)
MX (1) MXPA04011522A (es)
MY (1) MY142390A (es)
NO (1) NO330160B1 (es)
NZ (1) NZ536272A (es)
PL (1) PL212682B1 (es)
PT (1) PT1534390E (es)
RU (1) RU2284994C9 (es)
SI (1) SI1534390T1 (es)
TW (1) TWI280128B (es)
WO (1) WO2003098992A2 (es)
ZA (1) ZA200408701B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20070105824A1 (en) * 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
BRPI0516883A (pt) * 2004-10-25 2008-09-23 Ligand Pharm Inc compostos e métodos para modulação da atividade de trombopoietina
WO2007044982A2 (en) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
EP1951667A2 (en) * 2005-11-23 2008-08-06 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
EP2021846B1 (en) 2006-05-19 2017-05-03 Koninklijke Philips N.V. Ablation device with optimized input power profile
WO2008073864A1 (en) * 2006-12-12 2008-06-19 Smithkline Beecham Corporation Novel combinations
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
AU2012201288B2 (en) * 2007-05-03 2014-05-01 Novartis Ag Novel pharmaceutical composition
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8530508B2 (en) * 2007-10-09 2013-09-10 Glaxosmithkline Llc Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells
CN101481352A (zh) * 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
EA022756B1 (ru) 2009-04-01 2016-02-29 Плива Хрватска Д.О.О. Кристаллические формы элтромбопага и их применение
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
DK3127427T3 (da) 2009-05-29 2020-04-06 Novartis Ag Fremgangsmåder til administration af trombopoietinagonistforbindelser
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
US9440927B2 (en) 2011-09-13 2016-09-13 Glenmark Pharmaceuticals Limited Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US9770437B2 (en) 2013-09-02 2017-09-26 Hetero Research Foundation Compositions of eltrombopag
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
US10298884B2 (en) * 2014-05-09 2019-05-21 Honeywell International Inc. System and method of precision remote PTZ control of IP cameras
US10336706B2 (en) 2014-09-05 2019-07-02 Hetero Research Foundation Crystalline form of Eltrombopag free acid
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
EP3374349A1 (en) * 2015-11-10 2018-09-19 Amneal Pharmaceuticals Company GmbH Process for the preparation of eltrombopag olamine
CN106361719A (zh) * 2016-08-25 2017-02-01 浙江万晟药业有限公司 一种艾曲泊帕液体胶囊及其制备方法
CN106966984A (zh) * 2017-04-01 2017-07-21 常州制药厂有限公司 艾曲波帕二乙醇胺盐的制备方法
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
US11072586B2 (en) 2017-10-06 2021-07-27 Assia Chemical Industries Ltd. Solid state forms of eltrombopag choline
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
ES2815924T3 (es) 2018-08-02 2021-03-31 Fis Fabbrica Italiana Sintetici Spa Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
EP3604284B1 (en) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline eltrombopag monoethanolamine salt form d
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (es)
US851444A (en) 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
JPS58103432A (ja) * 1981-12-14 1983-06-20 富士写真フイルム株式会社 固体撮像素子を用いた内視鏡装置
ES8503669A1 (es) 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
SU1162799A1 (ru) * 1982-07-09 1985-06-23 Витебский государственный медицинский институт Способ получени 4-арилгидразонов пиразолидинтриона-3,4,5
FR2559483B1 (fr) 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
US4582831A (en) 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
EP0661170B1 (en) 1993-12-28 1998-09-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
US5482546A (en) 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
BR9608587A (pt) 1995-06-07 1999-01-05 Glaxo Group Ltd Composto que se liga ao receptor de trombopoietina composição farmacêutica e processo para o tratamento de um paciente sofrendo de um distúrbio
US5622818A (en) 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999022733A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
DE19851389A1 (de) 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
CO5210907A1 (es) 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
CN1376150A (zh) 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
ATE315934T1 (de) 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
HUP0001417A2 (hu) 2000-04-07 2002-12-28 Sanofi-Synthelabo Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények
US6214813B1 (en) 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US20020191179A1 (en) 2000-11-13 2002-12-19 Tukker Teunis Willem Measurement of surface defects
CA2436288A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1351979B1 (en) 2000-12-21 2008-01-16 Smithkline Beecham Corporation Regulated activation of cell-membrane receptors by metal-chelating agonists
WO2002059099A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
EP1354880A4 (en) 2001-01-26 2004-08-25 Shionogi & Co HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
AU2002333114B2 (en) 2001-11-30 2008-09-04 Qlt Inc. Hydrazonopyrazole derivatives and their use as therapeutics
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja) 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチン疑似体
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US20070105824A1 (en) 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline

Also Published As

Publication number Publication date
US8088813B2 (en) 2012-01-03
TWI280128B (en) 2007-05-01
PT1534390E (pt) 2010-03-08
WO2003098992A2 (en) 2003-12-04
US20140037580A1 (en) 2014-02-06
EP1534390A2 (en) 2005-06-01
IS7573A (is) 2004-11-30
ATE452683T1 (de) 2010-01-15
JP2010265317A (ja) 2010-11-25
CN100542530C (zh) 2009-09-23
PL372440A1 (en) 2005-07-25
CY1109912T1 (el) 2014-09-10
BRPI0310094B1 (pt) 2018-10-23
DK1534390T3 (da) 2010-04-26
NO330160B1 (no) 2011-02-28
US8846024B2 (en) 2014-09-30
EP1534390B1 (en) 2009-12-23
IL164966A0 (en) 2005-12-18
SI1534390T1 (sl) 2010-05-31
US20060178518A1 (en) 2006-08-10
RU2284994C2 (ru) 2006-10-10
US7547719B2 (en) 2009-06-16
US20090291995A1 (en) 2009-11-26
WO2003098992A3 (en) 2004-03-25
IL199438A (en) 2011-06-30
TW200407128A (en) 2004-05-16
US20110081312A1 (en) 2011-04-07
BRPI0310094B8 (pt) 2021-05-25
US20120189576A1 (en) 2012-07-26
CA2486697A1 (en) 2003-12-04
RU2004137491A (ru) 2005-06-10
ES2338108T3 (es) 2010-05-04
EP1534390A4 (en) 2008-03-12
BR0310094A (pt) 2005-02-15
IS2770B (is) 2011-12-15
AU2003241587B2 (en) 2007-10-04
ZA200408701B (en) 2006-02-22
RU2284994C9 (ru) 2021-02-24
KR20110113216A (ko) 2011-10-14
NZ536272A (en) 2007-08-31
US20150079030A1 (en) 2015-03-19
CA2486697C (en) 2009-01-06
US7795293B2 (en) 2010-09-14
KR20040106569A (ko) 2004-12-17
LTC1534390I2 (lt) 2020-06-10
JP4612414B2 (ja) 2011-01-12
NO20045561L (no) 2004-12-20
LTPA2010007I1 (lt) 2019-11-11
EP2206533A2 (en) 2010-07-14
AU2003241587A1 (en) 2003-12-12
HK1078039A1 (en) 2006-03-03
CN1652842A (zh) 2005-08-10
EP2206533A3 (en) 2010-09-15
MY142390A (en) 2010-11-30
JP2005526143A (ja) 2005-09-02
MXPA04011522A (es) 2005-02-14
DE60330674D1 (de) 2010-02-04
KR101090643B1 (ko) 2011-12-07
PL212682B1 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
AR040083A1 (es) Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
KR101093880B1 (ko) 프로테아좀 억제제 및 그의 사용 방법
JP2024029182A (ja) γｃサイトカイン活性を調節するための組成物および方法
US9096504B2 (en) Controlled chemical release of hydrogen sulfide
EP2115124B1 (en) Methods for increasing and mobilizing hematopoietic stem cells
EP2077826B1 (en) Method to enhance tissue regeneration
AR046188A1 (es) Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o
RU2747728C2 (ru) Применение размноженных популяций гематопоэтических стволовых клеток/клеток-предшественников
CA2455559A1 (en) Methods to mobilize progenitor/stem cells
AR032679A1 (es) Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz
CY1108114T1 (el) Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου
JP6920990B2 (ja) アルファ９インテグリンアンタゴニストおよびｃｘｃｒ４アンタゴニストを用いるｈｓｃの除去および放出
KR20150065881A (ko) 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물
PL185563B1 (pl) Pochodne kwasu nodulisporowego oraz zawierające je kompozycje farmaceutyczne
AU2014210669A1 (en) Isoprenyl compounds and methods thereof
US20160000864A1 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
KR20170106980A (ko) 이식 후에 조혈 줄기 세포의 생착 효능을 증가시키는데 사용하기 위한 조성물
RU2008129635A (ru) Ингибиторы ссr9 активности
KR20240047483A (ko) 감마-ｃ-사이토카인 활성의 조정
Honda et al. Synthesis and biological evaluation of 1-[2-cyano-3, 12-dioxooleana-1, 9 (11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent
US11191767B2 (en) Pharmaceutical composition for stimulating stem cell division and suppressing bacterial virulence
AR026022A1 (es) Metodo para el tratamiento de la obesidad
TWI650326B (zh) 醫藥組合物、化合物的用途及合成方法
KR101750658B1 (ko) 종양 표적화 광치료제 및 그 제조방법
JP2005512984A (ja) ジオキソランヌクレオシド類似体を含む白血病の治療のための医薬組成物

Legal Events

Date Code Title Description
FB Suspension of granting procedure